Algorae Pharmaceuticals (ASX: 1AI) achieved a key milestone in the recent June quarter, locking in a strategic partnership with the Victorian Centre for Functional Genomics (VCFG) at Melbourne’s Peter MacCallum Cancer Centre.
The partners are working on high-throughput experimental validation for 21 in silico predictions generated by the AI-enabled AlgoraeOS Version 1.0, alongside three drug combinations identified through conventional scientific methods.
They expect to release the initial pre-clinical results from the program within the next six months.
The trial is evaluating oncology-focused predictions across the brain, pancreas, breast, and prostate cancer cell lines.
It will focus on optimisation of cell growth kinetics and drug toxicity parameters, in vitro assessment of drug combination synergies and analysis of synergies across empirically-tested drug combinations, leveraging the ‘lab in the loop’ paradigm to enhance the predictive accuracy of AlgoraeOS.
Algorae said drug combinations that demonstrate synergistic inhibition of cancer cell proliferation may form the basis of novel therapeutic strategies for further investigation.
The company has steadily progressed development of its AlgoraeOS Version 2.0 during the quarter and anticipates delivery before year end, as per its previous guidance.
The 2.0 update features enhancements to improve prediction accuracy, scalability and performance.
It will include new model architecture, an object-oriented programming framework, high-performance multi-GPU processing, and multi-modality data integration.
Algorae confirmed that validation data from VCFG studies combined with cross-validation and synergy metrics would be incorporated into future platform releases for continuous improvement of predictive capabilities for synergistic drug combinations.
Algorae had a cash balance of $2.32 million at end June, supported by a research and development (R&D) rebate of $318,771 from the Australian government.
Net operating cash outflow for the quarter was $264,504, with $476,265 in R&D expenditure and $76,310 in payments to directors and related parties.
Algorae said it remained well-capitalised to achieve near-term clinical and commercial milestones, supported by robust intellectual property, strategic collaborations, and a capital-efficient AI-enabled drug discovery model.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。